Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 3, 2013, Pages 653-660

  Song, Taejong ^a   Kim, Min Kyu ^b   Lee, Yoo Young ^b   Choi, Chel Hun ^b   Kim, Tae Joong ^b   Lee, Jeong Won ^b   Kim, Byoung Gie ^b   Bae, Duk Soo ^b  

^a CHA University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Cisplatin; Ifosfamide; Ovarian cancer; Salvage therapy

Indexed keywords

CISPLATIN; IFOSFAMIDE;

ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HUMAN; KIDNEY DISEASE; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOCYTOPENIA; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IFOSFAMIDE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84883487330     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2241-7     Document Type: Article

References (29)

1. Marsden DE, Friedlander M, Hacker NF (2000) Current management of epithelial ovarian carcinoma: a review. Semin Surg Oncol 19:11-19
2. Kavanagh J, Tresukosol D, Edwards C, Freedman R, Gonzalez de Leon C, Fishman A, Mante R, Hord M, Kudelka A (1995) Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 13:1584-1588
3. Kavanagh JJ, Kudelka AP, de Leon CG, Tresukosol D, Hord M, Finnegan MB, Kim EE, Varma D, Forman A, Cohen P, Edwards CL, Freedman RS, Verschraegen CF (1996) Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 2:837-842
4. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393
5. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987-993
6. Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, Toner GC (1996) Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 63:89-93
7. Tresukosol D, Kudelka AP, Gonzales de Leon C, Edwards CL, Freedman RS, Mante R, Hord M, Kavanagh JJ (1996) Paclitaxel retreatment in patients with platinum and paclitaxel resistant ovarian cancer. Eur J Gynaecol Oncol 17:188-191
8. Dorval T, Soussain C, Beuzeboc P, Garcia-Giralt E, Jouve M, Livartowski A, Mosseri V, Palangie T, Scholl S, Sastre X, Pouillart P (1996) Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer. J Infus Chemother 6:47-49
9. Markman M, Kennedy A, Sutton G, Hurteau J, Webster K, Peterson G, Kulp B, Belinson J (1998) Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent. Gynecol Oncol 70:272-274
10. Scarfone G, Villa A, Parazzini F, Sciatta C, Polverino G, Bolis G (1999) A phase I-II trial of high-dose ifosfamide in patients with ovarian cancer refractory or resistant to platinum and/or paclitaxel-containing chemotherapy. Tumori 85:217-219
11. Shaheen M, Stender MJ, McClean JW, Look KY, Einhorn LH (2004) Phase II study of ifosfamide plus daily oral etoposide in previously treated ovarian cancer: a Hoosier Oncology Group (HOG) study. Am J Clin Oncol 27:229-231
12. Chiara S, Tognoni A, Pastrone I, Tomasello L, Brema F, Di Costanzo G, Folco U, Pronzato P (2004) Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer. Gynecol Oncol 93:474-478
13. Salar A, Martino R, Perea G, Ribera JM, Lopez-Guillermo A, Guardia R, Escoda L, Altes A, Sierra J, Montserrat E (2002) High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma. Haematologica 87:1028-1035
14. Joly F, Sevin E, Lortholary A, Priou F, Paitel JF, Fabbro M, Henry-Amar M, Hamond K, Bourgeois H (2010) Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: a multicenter phase II trial. Gynecol Oncol 116:312-316
15. Joly F, Bourgeois H, Floquet A, Chinet-Charrot P, Meyer F, Lebrun D, Hamond K, Leroy C, Heron JF (2006) Efficacy and tolerability of the ifosfamide-epirubicin combination in relapsed ovarian cancer. Int J Gynecol Cancer 16:77-82
16. Vanhoefer U, Schleucher N, Klaassen U, Seeber S, Harstrick A (2000) Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic. Semin Oncol 27:8-13
17. Polyzos A, Tsavaris N, Kosmas C, Petrikos G, Giannikos L, Kalahanis N, Papadopoulos O, Christodoulou K, Giannakopoulos K, Veslemes M, Katsilambros N (1999) Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide. J Chemother 11:144-149
18. Cervellino JC, Araujo CE, Sanchez O, Miles H, Nishihama A (1995) Cisplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix. A phase II trial. Acta Oncol 34:257-259
19. Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, Markman M, Benda J (2002) Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 20:1832-1837
20. Crotzer DR, Wolf JK, Gano JB, Gershenson DM, Levenback C (2007) A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary. Gynecol Oncol 105:399-403
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
22. Gronlund B, Høgdall C, Hilden J, Engelholm SA, Høgdall EV, Hansen HH (2004) Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol 22:4051-4058
23. Rustin GJ (2003) Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 21:187s-193s
24. Baur M, Fazeny-Doerner B, Hudec M, Sevelda P, Salzer H, Dittrich C (2006) Ifosfamide/mesna as salvage therapy in platinum pretreated ovarian cancer patients - long-term results of a phase II study. Cancer Invest 24:22-27
25. Sutton GP, Blessing JA, Homesley HD, Berman ML, Malfetano J (1989) Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 7:1672-1676
26. Sorensen P, Pfeiffer P, Bertelsen K (1995) A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy. Gynecol Oncol 56:75-78
27. Gonzalez-Martin A, Crespo C, Garcia-Lopez JL, Pedraza M, Garrido P, Lastra E, Moyano A (2002) Ifosfamide and vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimen. Gynecol Oncol 84:368-373
28. Polyzos A, Kosmas C, Tsavaris N, Toufexi H, Lagadas A, Gogas H, Giannakopoulos K, Kouraklis G, Griniatsos J, Felekouras E, Tsigris C, Nikiteas N, Papadopoulos O, Giannopoulos A (2007) Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel. Anticancer Res 27:1645-1651
29. Polyzos A, Tsavaris N, Gogas H, Lagadas A, Polyzos K, Giannakopoulos K, Felekouras E, Tsigris C, Karatzas T, Papadopoulos O, Giannopoulos A (2009) Cisplatin-Ifosfamide-gemcitabine as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and Paclitaxel. Anticancer Res 29:2681-2686